keyword
https://read.qxmd.com/read/38631035/fostering-digital-life-skills-through-social-media-with-adolescents-in-6-german-states-protocol-for-an-accessibility-study-according-to-the-re-aim-framework
#1
JOURNAL ARTICLE
Elizabeth Zimmermann, Samuel Tomczyk
BACKGROUND: Social media is essential in the lives of adolescents, with 97% of US teenagers engaging daily. While it facilitates communication, learning, and identity development, it also poses risks like harmful content exposure and psychological distress, particularly for adolescents in their critical developmental stage. Teaching digital life skills innovatively counters these risks, adapting traditional competencies such as decision-making, problem-solving, creative and critical thinking, communication, interpersonal skills, self-awareness, empathy, and emotional and stress management to digital challenges...
April 17, 2024: JMIR Research Protocols
https://read.qxmd.com/read/38631029/mutual-associations-of-exposure-to-ambient-air-pollutants-in-the-first-1000-days-of-life-with-asthma-wheezing-in-children-prospective-cohort-study-in-guangzhou-china
#2
JOURNAL ARTICLE
Fenglin Tian, Xinqi Zhong, Yufeng Ye, Xiaohan Liu, Guanhao He, Cuiling Wu, Zhiqing Chen, Qijiong Zhu, Siwen Yu, Jingjie Fan, Huan Yao, Wenjun Ma, Xiaomei Dong, Tao Liu
BACKGROUND: The first 1000 days of life, encompassing pregnancy and the first 2 years after birth, represent a critical period for human health development. Despite this significance, there has been limited research into the associations between mixed exposure to air pollutants during this period and the development of asthma/wheezing in children. Furthermore, the finer sensitivity window of exposure during this crucial developmental phase remains unclear. OBJECTIVE: This study aims to assess the relationships between prenatal and postnatal exposures to various ambient air pollutants (particulate matter 2...
April 17, 2024: JMIR Public Health and Surveillance
https://read.qxmd.com/read/38631003/overall-survival-with-adjuvant-pembrolizumab-in-renal-cell-carcinoma
#3
JOURNAL ARTICLE
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stephane Oudard, Delphine Topart, Hans Hammers, Hiroshi Kitamura, David F McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E Burgents, Rodolfo F Perini, Thomas Powles
BACKGROUND: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent...
April 18, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38630995/chemokine-receptor-4-targeted-pet-ct-with-68ga-pentixather-detects-more-lesions-than-68ga-pentixafor-pet-ct-in-multiple-myeloma
#4
JOURNAL ARTICLE
Qiao Yang, Fujing Zhang, Zhixin Hao, Junling Zhuang, Li Huo
An 83-year-old woman with newly diagnosed multiple myeloma (MM) was enrolled in our 68Ga-pentixather and 68Ga-pentixafor PET/CT trial for evaluation of tumor burden. 68Ga-pentixather PET/CT detected more focal bone lesions, and the uptake levels of focal bone lesions on 68Ga-pentixather PET/CT were higher than those on 68Ga-pentixafor PET/CT. This suggests that 68Ga-pentixather PET/CT may be an alternative imaging modality and more sensitive in detecting MM lesions than 68Ga-pentixafor PET/CT.
April 17, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38630962/one-year-longitudinal-assessment-of-patients-with-cmt1a-using-quantitative-mri
#5
JOURNAL ARTICLE
Etienne Fortanier, Marc Adrien Hostin, Constance Michel, Emilien Delmont, Marc-Emmanuel Bellemare, Maxime Guye, David Bendahan, Shahram Attarian
BACKGROUND AND OBJECTIVES: Intramuscular fat fraction (FF) assessed using quantitative MRI (qMRI) has emerged as one of the few responsive outcome measures in CMT1A suitable for future clinical trials. This study aimed to identify the relevance of multiple qMRI biomarkers for tracking longitudinal changes in CMT1A and to assess correlations between MRI metrics and clinical parameters. METHODS: qMRI was performed in CMT1A patients at 2 time points, a year apart, and various metrics were extracted from 3-dimensional volumes of interest at thigh and leg levels...
May 14, 2024: Neurology
https://read.qxmd.com/read/38630954/phase-ii-single-arm-trial-of-induction-and-concurrent-vismodegib-with-curative-intent-radiation-therapy-for-locally-advanced-unresectable-basal-cell-carcinoma
#6
JOURNAL ARTICLE
Christopher A Barker, Suzanne Dufault, Sarah T Arron, Alan L Ho, Alain P Algazi, Lara A Dunn, Audrey A Humphries, Carter Hultman, Ming Lian, P Daniel Knott, Sue S Yom
PURPOSE: Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients with LA BCC. METHODS: In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT...
April 17, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38630952/case-control-study-of-individuals-with-small-fiber-neuropathy-after-covid-19
#7
JOURNAL ARTICLE
Lindsay McAlpine, Adeel S Zubair, Phillip Joseph, Serena Spudich
OBJECTIVES: To report a case-control study of new-onset small fiber neuropathy (SFN) after COVID-19 with invasive cardiopulmonary exercise testing (iCPET). SFN is a critical objective finding in long COVID and amenable to treatment. METHODS: A retrospective chart review was conducted on patients seen in the NeuroCOVID Clinic at Yale who developed new-onset SFN after a documented COVID-19 illness. We collected demographics, symptoms, skin biopsy, iCPET testing, treatments, and clinical response to treatment or no intervention...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38630908/safety-and-efficacy-of-belantamab-mafodotin-with-pembrolizumab-in-patients-with-relapsed-or-refractory-multiple-myeloma
#8
JOURNAL ARTICLE
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke, Albert Oriol, Peter M Voorhees, Aranzazu A Alonso, Natalie S Callander, María-Victoria Mateos, Nishitha Reddy, Shawn Hakim, John LaMacchia, Nashita Patel, Danaé Williams, Roxanne C Jewell, Xiangdong Zhou, Ira Gupta, Joanna Opalinska, Ajay K Nooka
BACKGROUND: Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell-mediated antitumor responses. This study investigated the efficacy and safety of belamaf with pembrolizumab in patients with RRMM. METHODS: DREAMM-4 (NCT03848845) was an open-label, single-arm, phase 1/2 study divided into dose-escalation (part 1) and dose-expansion (part 2) phases...
April 17, 2024: Cancer
https://read.qxmd.com/read/38630903/outcome-prioritization-and-preferences-among-older-adults-with-cancer-starting-chemotherapy-in-a-randomized-clinical-trial
#9
JOURNAL ARTICLE
Enrique Soto-Perez-de-Celis, William Dale, Vani Katheria, Heeyoung Kim, Marwan Fakih, Vincent M Chung, Dean Lim, Joanne Mortimer, Leana Cabrera Chien, Kemeberly Charles, Elsa Roberts, Jessica Vazquez, Jeanine Moreno, Ty Lee, Simone Fernandes Dos Santos Hughes, Mina S Sedrak, Can-Lan Sun, Daneng Li
INTRODUCTION: Older adults with cancer facing competing treatments must prioritize between various outcomes. This study assessed health outcome prioritization among older adults with cancer starting chemotherapy. METHODS: Secondary analysis of a randomized trial addressing vulnerabilities in older adults with cancer. Patients completed three validated outcome prioritization tools: 1) Health Outcomes Tool: prioritizes outcomes (survival, independence, symptoms) using a visual analog scale; 2) Now vs...
April 17, 2024: Cancer
https://read.qxmd.com/read/38630885/editorial-the-role-of-vitamin-d-metabolites-in-the-evaluation-of-bone-health-are-they-physiologically-relevant
#10
EDITORIAL
Eva S Liu, Meryl S LeBoff
No abstract text is available yet for this article.
March 4, 2024: Journal of Bone and Mineral Research
https://read.qxmd.com/read/38630873/induced-regulatory-t-cells-as-immunotherapy-in-allotransplantation-and-autoimmunity-challenges-and-opportunities
#11
JOURNAL ARTICLE
Evelyn Katy Alvarez-Salazar, Arimelek Cortés-Hernández, Saúl Arteaga-Cruz, Gloria Soldevila
Regulatory T cells (Tregs) play a crucial role in the homeostasis of the immune response. Tregs are mainly generated in the thymus and are characterized by the expression of Foxp3, which is considered the Treg master transcription factor. In addition, Tregs can be induced from naïve CD4+ T cells to express Foxp3 under specific conditions both in vivo (pTregs) and in vitro (iTregs). Both subsets tTregs and pTregs are necessary for the establishment of immune tolerance to self and non-self antigens. Although it has been postulated that iTregs may be less stable compared to tTregs, mainly due to epigenetic differences, accumulating evidence in animal models shows that iTregs are stable in vivo and could be used for the treatment of inflammatory disorders including autoimmune diseases and allogeneic transplant rejection...
April 17, 2024: Journal of Leukocyte Biology
https://read.qxmd.com/read/38630847/deep-learning-assists-detection-of-esophageal-cancer-and-precursor-lesions-in-a-prospective-randomized-controlled-study
#12
JOURNAL ARTICLE
Shao-Wei Li, Li-Hui Zhang, Yue Cai, Xian-Bin Zhou, Xin-Yu Fu, Ya-Qi Song, Shi-Wen Xu, Shen-Ping Tang, Ren-Quan Luo, Qin Huang, Ling-Ling Yan, Sai-Qin He, Yu Zhang, Jun Wang, Shu-Qiong Ge, Bin-Bin Gu, Jin-Bang Peng, Yi Wang, Li-Na Fang, Wei-Dan Wu, Wen-Guang Ye, Min Zhu, Ding-Hai Luo, Xiu-Xiu Jin, Hai-Deng Yang, Jing-Jing Zhou, Zhen-Zhen Wang, Jian-Fen Wu, Qiao-Qiao Qin, Yan-di Lu, Fei Wang, Ya-Hong Chen, Xia Chen, Shan-Jing Xu, Tao-Hsin Tung, Chen-Wen Luo, Li-Ping Ye, Hong-Gang Yu, Xin-Li Mao
Endoscopy is the primary modality for detecting asymptomatic esophageal squamous cell carcinoma (ESCC) and precancerous lesions. Improving detection rate remains challenging. We developed a system based on deep convolutional neural networks (CNNs) for detecting esophageal cancer and precancerous lesions [high-risk esophageal lesions (HrELs)] and validated its efficacy in improving HrEL detection rate in clinical practice (trial registration ChiCTR2100044126 at www.chictr.org.cn). Between April 2021 and March 2022, 3117 patients ≥50 years old were consecutively recruited from Taizhou Hospital, Zhejiang Province, and randomly assigned 1:1 to an experimental group (CNN-assisted endoscopy) or a control group (unassisted endoscopy) based on block randomization...
April 17, 2024: Science Translational Medicine
https://read.qxmd.com/read/38630838/effect-of-extracorporeal-shock-wave-on-upper-trapezius-trigger-points-in-patients-with-cervicogenic-headache-a-randomized-clinical-trial
#13
JOURNAL ARTICLE
Radwa F Hammam, Ahmed M Alshimy, Omar M Elabd, Aliaa M Elabd
OBJECTIVE: A recent study was designed to ascertain the impact of extracorporeal shock wave therapy (ESWT) on upper trapezius trigger points in cervicogenic headaches patients. DESIGN: A double-blinded randomized controlled trial study, in which 50 participants (11 male and 39 female) aged between 20-40 with cervicogenic headache were subdivided with randomization to group (A), which received traditional physical therapy and sham shock wave therapy, and group (B), which received traditional physical therapy and actual shock wave therapy...
April 4, 2024: American Journal of Physical Medicine & Rehabilitation
https://read.qxmd.com/read/38630790/diffuse-pleural-mesotheliomas-with-genomic-near-haploidization-a-newly-recognized-subset-with-distinct-clinical-histologic-and-molecular-features
#14
JOURNAL ARTICLE
Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A Febres Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B Villafania, Jennifer L Sauter, Michael Offin, Marjorie G Zauderer, Marc Ladanyi
PURPOSE: Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA project; however, its clinicopathologic and molecular features remain poorly defined. EXPERIMENTAL DESIGN: We analyzed clinical genomic profiling data from 290 patients with DPM using the MSK-IMPACT assay. Allele-specific copy number analysis was performed using the FACETS algorithm. RESULTS: 210 patients were evaluable for LOH analysis using FACETS...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38630755/spatially-preserved-multi-region-transcriptomic-subtyping-and-biomarkers-of-chemoimmunotherapy-outcome-in-extensive-stage-small-cell-lung-cancer
#15
JOURNAL ARTICLE
Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, Cristina Marti, Manuel Cobo, Vanesa Gutiérrez, Manuel Dómine, Jose Fuentes, Margarita Majem, Javier de Castro, Juan Felipe Cordoba, Maria Pilar Diz, Dolores Isla, Emilio Esteban, Enric Carcereny, Laia Vila, Alberto Moreno-Vega, Silverio Ros, Amaia Moreno, Francisco Javier Garcia, Gerardo Huidobro, Carlos Aguado, Victor Cebey-Lopez, Javier Valdivia, Ramon Palmero, Pilar Lianes, Marta Lopez-Brea, Oscar Juan Vidal, Mariano Provencio, Edurne Arriola, Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Angel Nuñez-Buiza, Álvaro Ucero, Susana Hernandez, Fernando Lopez-Rios, Esther Conde, Luis Paz-Ares, Jon Zugazagoitia
BACKGROUND: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small-cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC. PATIENTS AND METHODS: We analyzed tumor samples from 58 ES-SCLC patients enrolled in two multicenter single-arm phase IIIb studies evaluating front-line chemoimmunotherapy in Spain: n=32 from the IMfirst trial, and n=26 from the CANTABRICO trial...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38630728/effect-of-care-bundles-for-acute-kidney-injury-a-systematic-review-and-meta-analysis
#16
JOURNAL ARTICLE
Shuzhen Zhang, Yixin Chen, Fangfang Zhou, Lailiang Wang, Qun Luo
PURPOSE: Acute kidney injury (AKI) is frequent among in-hospital patients with high incidence and mortality. Implementing a series of evidence-based AKI care bundles may improve patient outcomes by reducing changeable standards of care. The aim of this meta-analysis was therefore to appraise the influences of AKI care bundles on patient outcomes. MATERIALS AND METHODS: We explored three international databases (PubMed, Embase, and Cochrane Central Register of Controlled Trials) and two Chinese databases (Wanfang Data and China National Knowledge Infrastructure) for studies from databases inception until November 30, 2022, comparing the impact of different AKI care bundles with usual standards of care in patients with or at risk for AKI...
2024: PloS One
https://read.qxmd.com/read/38630683/large-language-models-approach-expert-level-clinical-knowledge-and-reasoning-in-ophthalmology-a-head-to-head-cross-sectional-study
#17
JOURNAL ARTICLE
Arun James Thirunavukarasu, Shathar Mahmood, Andrew Malem, William Paul Foster, Rohan Sanghera, Refaat Hassan, Sean Zhou, Shiao Wei Wong, Yee Ling Wong, Yu Jeat Chong, Abdullah Shakeel, Yin-Hsi Chang, Benjamin Kye Jyn Tan, Nikhil Jain, Ting Fang Tan, Saaeha Rauz, Daniel Shu Wei Ting, Darren Shu Jeng Ting
Large language models (LLMs) underlie remarkable recent advanced in natural language processing, and they are beginning to be applied in clinical contexts. We aimed to evaluate the clinical potential of state-of-the-art LLMs in ophthalmology using a more robust benchmark than raw examination scores. We trialled GPT-3.5 and GPT-4 on 347 ophthalmology questions before GPT-3.5, GPT-4, PaLM 2, LLaMA, expert ophthalmologists, and doctors in training were trialled on a mock examination of 87 questions. Performance was analysed with respect to question subject and type (first order recall and higher order reasoning)...
April 2024: PLOS Digit Health
https://read.qxmd.com/read/38630656/recent-progress-of-small-interfering-rna-delivery-on-the-market-and-clinical-stage
#18
REVIEW
Fan Guo, Yan Li, Wenjun Yu, Yuanlei Fu, Jing Zhang, Haiqiang Cao
Small interfering RNAs (siRNAs) are promising therapeutic strategies, and five siRNA drugs have been approved by the Food and Drug Administration (FDA) and the European Commission (EC). This marks a significant milestone in the development of siRNA for clinical applications. The approved siRNA agents can effectively deliver siRNAs to the liver and treat liver-related diseases. Currently, researchers have developed diverse delivery platforms for transporting siRNAs to different tissues such as the brain, lung, muscle, and others, and a large number of siRNA drugs are undergoing clinical trials...
April 17, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38630651/using-gps-and-self-report-data-to-examine-the-relationship-between-community-mobility-and-community-participation-among-autistic-young-adults
#19
JOURNAL ARTICLE
Eugene Brusilovskiy, Mark S Salzer, Amber Pomponio Davidson, Cecilia Feeley, Beth Pfeiffer
IMPORTANCE: Community participation of autistic adults is important for health and well-being. Many clinical efforts and interventions aim to enhance community participation in this population. OBJECTIVE: To empirically examine the relationship between community participation and community mobility. DESIGN: A randomized controlled trial using data from baseline and 4- to 6-wk follow-up. SETTING: Community organizations serving autistic adults in Philadelphia...
May 1, 2024: American Journal of Occupational Therapy: Official Publication of the American Occupational Therapy Association
https://read.qxmd.com/read/38630620/mast-cells-a-novel-therapeutic-avenue-for-cardiovascular-diseases
#20
JOURNAL ARTICLE
Remo Poto, Gianni Marone, Stephen J Galli, Gilda Varricchi
Mast cells are tissue-resident immune cells strategically located in different compartments of the normal human heart (the myocardium, pericardium, aortic valve and close to nerves) as well as in atherosclerotic plaques. Cardiac mast cells produce a broad spectrum of vasoactive and proinflammatory mediators, which have potential roles in inflammation, angiogenesis, lymphangiogenesis, tissue remodeling and fibrosis. Mast cells release preformed mediators (e.g., histamine, tryptase, chymase) and de novo synthesized mediators [e...
April 17, 2024: Cardiovascular Research
keyword
keyword
909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.